{
  "id": 5620541,
  "title": "Is Gilead Sciences Stock Outperforming the S&P 500?",
  "url": "https://urgent.news/2026/09/03/is-gilead-sciences-stock-outperforming-the-s-p-500",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-03T09:56:24.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/gilead-sciences-stock-outperforming-p-095624149.html"
  },
  "original_language": "en",
  "account": "Gilead Sciences, Inc. (GILD), a Foster City, California-based pharmaceutical company, specializes in creating medicines for unmet medical needs both in the United States and globally. With a substantial market capitalization of $185.9 billion, GILD operates within the large-cap segment of the drug manufacturing industry. The company's portfolio includes Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo, which are used to treat HIV-1 infection in patients, along with other related pharmaceuticals.\n\nGILD's stock has demonstrated strong performance, trading above its 200-day moving average since August and above its 50-day moving average since late July. In fact, the stock has risen 17.3% over the past three months, outpacing the S&P 500 Index ($SPX), which has only seen a marginal increase during the same period. Furthermore, GILD has surpassed the broader market in the long term, with a 32.7% growth over the past 52 weeks, compared to the SPX's 19.5% return during the same timeframe.\n\nA significant milestone for GILD occurred on June 24, when the U.S. Food and Drug Administration (FDA) approved its Trodelvy (sacituzumab govitecan-hziy), a novel antibody-drug conjugate. This approval marks the first-in-class Trop-2-directed treatment for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). The drug's practice-changing role as a first-line treatment option available for all patients, regardless of PD-L1 status, has bolstered the company's drug pipeline and advanced treatment options for more aggressive forms of breast cancer.\n\nIn comparison to its peer, Amgen Inc. (AMGN), GILD has underperformed over the past year. While AMGN stock has grown by 54.3%, GILD's stock has only increased by 32.7%. Despite this, Wall Street maintains a highly bullish outlook for GILD, with 30 analysts tracking the stock, and the overall consensus rating being a Strong Buy. The average price target for GILD stands at $159.10, representing a 6.3% upside potential from the current stock price.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}